Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 27 Apr 2026
The U.S. Department of Justice said on Thursday it would immediately loosen restrictions on some marijuana products and move quickly to reclassify the drug as less...
Read Full NewsIZAR-1: Sonelokimab Meets Phase 3 End Points for PsA
Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.
Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.
What The FDA Psychedelic Hearing Means for Psychiatrists
A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.
A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.
Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.
1.
AI-based breast cancer risk technology receives FDA breakthrough device designation
2.
De-escalation Misses the Mark in Inflammatory Breast Cancer
3.
An Examine More Into the Acceptance of CRISPR/Cas9 Gene Therapy for Sickle Cell Illness.
4.
Promising for Monitoring and Diagnosis of AD is the finger-prick test.
5.
Genomic Newborn Screening Could Identify Childhood Cancer Predisposition
1.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
2.
Artificial Intelligence for Modeling Tumor Ecosystem Dynamics
3.
HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option
4.
Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy
5.
Personalized Tumor Ecological Landscapes in Oncology
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- The Conclusion
3.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VIII
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge